Compare HCA Health Inc (HCA) vs Invesco Ltd. (IVZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HCA Health Inc vs Invesco Ltd. — how do they compare? HCA Health Inc trades at $451.09 (market cap $96.35B), while Invesco Ltd. trades at $29.51 (market cap $13.28B). The key difference: HCA Health Inc is far larger — about 7.3× Invesco Ltd.'s market cap, and Invesco Ltd. pays the higher dividend (2.86%). Which is the better fit depends on your goals — on Pluang, investors hold HCA Health Inc for 76 Days and Invesco Ltd. for 77 Days on average.
| HCA | IVZ | |
|---|---|---|
Market Cap | $96.35B | $13.28B |
Volume | 1,079,453 | 3,698,033 |
Sector | Health | Financials |
52-Week High | $545.13 | $33.31 |
52-Week Low | $361.32 | $22.44 |
Typical Hold Time | 76 Days | 77 Days |
Enterprise Value | $146.88B | $23.45B |
Dividend Yield | 0.7% | 2.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HCA Healthcare trades at $451.09, up 2.71% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q4 2025 and Q1-Q2 2026 exceeding expectations, supported by robust revenue growth from $70.6B in 2024 to $75.6B in 2025. Valuation metrics remain attractive with P/E of 14.92 and P/S of 1.31, while technical indicators signal bullish momentum above key support levels.
The outlook remains positive with 63% analyst buy ratings and $461.12 consensus target, though legal investigations and high debt levels pose risks. Revenue growth and operational efficiency provide upside potential, but investors should monitor regulatory developments and debt management closely given the 80.9% debt-to-asset ratio in 2025.
Invesco (IVZ) trades at $29.51, down 3.25% today, with bearish technical signals dominating. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026, while Q3 2026 results are pending. Despite negative net income margins in 2025, operating cash flow remains strong at $1.53 billion, and analyst consensus leans toward Hold with a $33.71 price target. Recent news highlights ETF expansions and AUM growth to $2.56 trillion in August 2026.
The outlook is cautious; IVZ faces profitability challenges with negative ROE and net margins, but solid cash flow and analyst buy ratings (42.86%) suggest recovery potential. Risks include earnings volatility and competitive ETF pressures, while institutional sentiment is neutral. The stock's current price near the low end of analyst targets ($28-$41) may appeal to value investors betting on operational improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →
